This is a prospective trial of Revlimid for subjects who have a blood cell cancer called
myelodysplastic syndrome (MDS). Cells in their marrow make proteins through messages that are
carried from the genes. The amount of the message tells researchers if the protein it is
going to make is high or low. This is known as expression of genes. The purpose of this study
is to conduct a prospective trial testing the idea that expression of specific genes can help
to predict which patients will respond to study drug administration with Revlimid
(lenalidomide).